Resumen

MIJARES, Mercedes et al. Eficacia comparativa de dos presentaciones de clopidogrel en la inhibición de la agregación plaquetaria. AVFT [online]. 2008, vol.27, n.1, pp.86-89. ISSN 0798-0264.

Objective: To compare the efficacy of two presentations of clopidogrel in the Inhibition of Platelet Aggregation (IPA). Methods: Prospective study, sequential, in 22 healthy volunteers, 8 women and 14 men, aged between 21 and 55 years, median 30 years. We tested Platelet Aggregation (PA), with ADP 4µM and 10 µM, to exclude platelet disease. All received clopidogrel (Cirgrel ®), 75 mg daily for 15 days and PA was tested. After 30 days, they received clopidogrel (Plavix ®) for 15 days and PA was tested to compare the effects. Results: Means PA baseline were 66.45±7.00% and 66.45±7.88% respectively for each concentration. The averages of IPA with clopidogrel (Cirgrel®), were 30.21±19.51% and 28.96±21.75%, and clopidogrel (Plavix®) 35.64±24.84% and 30.91±27.4% (p = 0.45 and 0.81) respectively for each concentration of ADP. Conclusion: There were no significant differences, so that we can conclude that these two clopidogrel presentations are equivalents.

Palabras clave : Clopidogrel; platelet aggregation.